The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease

Clinical and Vaccine Immunology

Volumn 19, Issue 12, 2012, Pages 1921-1931

  Darsley, Michael J ^a,d   Chakraborty, Subhra ^b   DeNearing, Barbara ^b   Sack, David A ^b   Feller, Andrea ^b   Buchwaldt, Charlotte ^a   Bourgeois, A Louis ^c   Walker, Richard ^c   Harro, Clayton D ^b  

^a TD Vaccines A/S   (Denmark)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c PATH   (United States)

^d MD Biologic   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACE 527; BACTERIAL ANTIGEN; COLONIZATION FACTOR ANTIGEN I; ENTEROTOXIN; ESCHERICHIA COLI VACCINE; LIVE VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL SHEDDING; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CHILL; CLINICAL PROTOCOL; CONTROLLED STUDY; DEFECATION URGENCY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROTOXIGENIC ESCHERICHIA COLI; FECES CULTURE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LOOSE FECES; MALAISE; MALE; MORBIDITY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BACTERIAL LOAD; DIARRHEA; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; FECES; HUMAN EXPERIMENTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VACCINATION; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84870419742     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00364-12     Document Type: Article

References (34)

1. Black RE, et al. 2010. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375:1969-1987.
2. Boschi-Pinto C, Velebit L, Shibuya K. 2008. Estimating child mortality due to diarrhoea in developing countries. Bull. World Health Organ. 86:710-717.
3. Carpenter CM, et al. 2006. Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers. Vaccine 24:3709-3718.
4. Cohen D, et al. 2000. Safety and immunogenicity of two different lots of the oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Israeli young adults. Infect. Immun. 68:4492-4497. (Pubitemid 30497715)
5. Collett D. 2002. Modelling binary data, 2nd ed. Chapman & Hall/CRC, Boca Raton, FL.
6. Coster TS, et al. 2007. Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli. Infect. Immun. 75:252-259. (Pubitemid 46047900)
7. Dillingham R, Guerrant RL. 2004. Childhood stunting: measuring and stemming the staggering costs of inadequate water and sanitation. Lancet 363:94-95. (Pubitemid 38068321)
8. Evans DG, Evans DJ, Jr, Opekun AR, Graham DY. 1988. Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes. FEMS Microbiol. Immunol. 1:117-125.
9. Evans DG, Silver RP, Evans DJ, Jr, Chase DG, Gorbach SL. 1975. Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans. Infect. Immun. 12:656-667.
10. Evans DJ, Jr, Evans DG. 1973. Three characteristics associated with enterotoxigenic Escherichia coli isolated from man. Infect. Immun. 8:322-328.
11. Evans DJ, Jr, Evans DG, Opekun AR, Graham DY. 1988. Immunoprotective oral whole cell vaccine for enterotoxigenic Escherichia coli diarrhea prepared by in situ destruction of chromosomal and plasmid DNA with colicin E2. FEMS Microbiol. Immunol. 1:9-18.
12. FDA. Accessed 19 October 2012. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074775.htm.
13. Frech SA, et al. 2008. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 371:2019-2025.
14. Freedman DJ, et al. 1998. Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli. J. Infect. Dis. 177:662-667. (Pubitemid 28099880)
15. Graham DY, Estes MK, Gentry LO. 1983. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers. Gastroenterology 85:1017-1022. (Pubitemid 13007791)
16. Harro C, et al. 2011. Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin. Vaccine Immunol. 18:1719-1727.
17. Harro C, et al. 2011. A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults. Clin. Vaccine Immunol. 18:2118-2127.
18. Intercell. 7 December 2010. Intercell provides update on clinical trials for the patch-based travelers' diarrhea vaccine. Intercell, Vienna, Austria. http://www.intercell.com/main/company/news/news-full/article/ intercell-provides-update-on-clinical-trials-for-the-patch-based-travelers- diarrhea-vaccine/.
19. Levine M, Morris J, Losonsky G, Boedeker E, Lowe B. 1986. Fimbriae (pili) adhesins as vaccines, p 143-145. In Lark D, Normark S, Uhlin B-E, Wolf-Watz H (ed), Protein-carbohydrate interactions in biological systems: the molecular biology of microbial pathogenicity. Academic Press, London, United Kingdom.
20. Levine MM, et al. 1982. Reactogenicity, immunogenicity and efficacy studies of Escherichia coli type 1 somatic pili parenteral vaccine in man. Scand. J. Infect. Dis. Suppl. 33:83-95. (Pubitemid 13247836)
21. McKenzie R, et al. 2006. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect. Immun. 74:994-1000. (Pubitemid 43185535)
22. McKenzie R, et al. 2007. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25:3684-3691. (Pubitemid 46584755)
23. McKenzie R, et al. 2008. A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enteroxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC. Vaccine 26:4731-4739.
24. Moore SR, et al. 2010. Prolonged episodes of acute diarrhea reduce growth and increase risk of persistent diarrhea in children. Gastroenterology 139:1156-1164.
25. Petri WA, Jr, et al. 2008. Enteric infections, diarrhea, and their impact on function and development. J. Clin. Invest. 118:1277-1290.
26. Porter CK, et al. 2011. A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). Vaccine 29:5869-5885.
27. Qadri F, et al. 2006. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups. Vaccine 24:1726-1733. (Pubitemid 43238251)
28. Steffen R, Castelli F, Dieter Nothdurft H, Rombo L, Jane Zuckerman N. 2005. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J. Travel Med. 12:102-107. (Pubitemid 40593477)
29. Svennerholm A-M, Savarino SJ. 2004. Oral inactivated whole cell B subunit combination vaccine against enterotoxigenic Escherichia coli, p 1490-1517. In Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF (ed), New generation vaccines, 3rd ed. Marcel Dekker, Inc., New York, NY.
30. Tacket C, Levine M. 1997. Vaccines against enterotoxigenic Escherichia coli infections. II. Live oral vaccines and subunit (purified fimbriae and toxin subunit) vaccines, p 875-883. In Levine M, Woodrow G, Kaper J, Cobon G (ed), New generation vaccines, 2nd ed. Marcel Dekker, Inc., New York, NY.
31. Tacket CO, et al. 1988. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N. Engl. J. Med. 318:1240-1243.
32. Wang M, Szucs TD, Steffen R. 2008. Economic aspects of travelers' diarrhea. J. Travel Med. 15:110-118. (Pubitemid 351393035)
33. WHO. 2009, posting date. Diarrhoeal diseases; enterotoxigenic Escherchia coli (ETEC). WHO, Geneva, Switzerland. http://www.who.int/vaccine-research/ diseases/diarrhoeal/en/index4.html.
34. WHO. 2006. Future directions for research on enterotoxigenic Escherichia coli vaccines for developing countries. Wkly. Epidemiol. Rec. 81:97-104.